AI Summary
This article highlights a report from the US Federal Trade Commission revealing that pharmacy benefit managers in the USA are overcharging patients for cancer medicines. Additionally, they are channeling the dispensing of cancer drugs to their affiliated pharmacies, limiting patient access to quality cancer treatment. This practice ultimately endangers patients' lives.
A report from the US Federal Trade Commission (FTC) shows how pharmacy benefit managers in the USA are overcharging patients for cancer medicines and shifting dispensing of cancer drugs to their own affiliated pharmacies for profit, ultimately restricting patients’ access to quality cancer treatment and jeopardising their lives.